Please provide your email address to receive an email when new articles are posted on . In a new study, interleukin-1-beta inhibition with IV canakinumab in patients hospitalized with COVID-19, ...

Credit: Getty Images. Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to interleukin-1beta. A phase 3 trial evaluating canakinumab in combination with ...

(HealthDay News) — Canakinumab at a dose of 150 mg every 3 months is associated with reduced rate of cardiovascular events among patients with previous myocardial infarction, according to a study ...

Please provide your email address to receive an email when new articles are posted on . Canakinumab reduced total CV events in patients with prior MI and residual inflammatory risk, according to new ...

hba1c hemoglobin diabetes test The new analysis focuses on the remaining 4,960 patients, who had prediabetes at the start of the trial. Canakinumab (Ilaris; Novartis), an interleukin-1β blocker, did ...

NHS England » Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) ...

Recognition that three unrelated rare fever syndromes are all mediated by a single interleukin opened a new approach for controlling flares in the diseases. A clinical trial including cohorts of ...

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to ...

Previous studies had indicated that treatments for the rare condition known as VEXAS were either not very effective or came with major side effects. Interleukin-1 inhibitors are among the treatments ...

When Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer (NSCLC), the Swiss pharma played up signs that it said supported continued exploration of the med in ...

Novartis said on Tuesday its drug canakinumab (ACZ885) did not meet the primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer in a Phase III study, ...

The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti–interleukin-1β monoclonal ...